ImmunoGenesis Announces the Formation of Scientific Advisory Board
HOUSTON , July 1, 2025 /CNW/ -- ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies is encouraged by the early performance of IMGS-001 in the ongoing Phase 1a dose escalation study in adult patients with locally advanced or metastatic solid tumors refractory to standard-of-care treatment. To advise on the clinical development strategy for IMGS-001 and other pipeline agents, the company is proud to announce the appointment of a six-member Scientific Advisory Board (SAB) who recently met to review our clinical data and provide input on the upcoming next phase of the IMGS-001 Phase 1a/ 1b study.
"These distinguished members are true leaders in the field of immuno-oncology and come from some of the world's most prestigious cancer centers," said James Barlow , President and CEO of ImmunoGenesis. "I'm honored that the company can collaborate with this esteemed group of scientific and clinical experts whose insights will be instrumental in maximizing the potential of our lead agent to make a meaningful impact in treating some of the most challenging cancers."
More details on the newly formed SAB are at the following link: https://www.immunogenesis.com/team/
About ImmunoGenesis
ImmunoGenesis is a clinical-stage biotech company dedicated to transforming immuno-oncology by targeting key mechanisms of immune resistance. The company's lead product, IMGS-001, is a cytotoxic, dual-specific PD-L1/PD-L2 antibody currently in a Phase 1a/b clinical trial for the treatment of immune-excluded ("cold") tumors, which account for more than half of all cancers. In addition to its lead program, the company has a second clinical asset, IMGS-101 that has the potential to reverse tumor hypoxia, a major immunosuppressive element in solid tumors. The company has additional agents in the pipeline which represent novel approaches to overcome immune resistance in cold tumors. ImmunoGenesis designs therapies to address the pathology of these tumors, overcoming immune exclusion to elicit a robust immune response. For more information, visit www.immunogenesis.com.
About IMGS-001, a PD-L1/PD-L2 Dual-Specific Inhibitor
IMGS-001 is a PD-L1/PD-L2 dual-specific inhibitor with engineered cytotoxic effector function. It is the first molecule to target PD-L2 in addition to PD-L1, potentially shutting down the entire PD-1 pathway and providing a superior blockade compared to other PD-1 or PD-L1 inhibitors. Its engineered effector function enables IMGS-001 to kill immunosuppressive PD-L1- and/or PD-L2-expressing cells present in the tumor microenvironment, providing the potential to overcome immune resistance in immune-excluded tumors. Preclinical data showed that IMGS-001 drove superior survival rates and tumor growth inhibition in head-to-head studies compared to currently available immunotherapies. With its cytotoxic killing function and superior blockade, IMGS-001 may provide a new foundation for combination immuno-oncology therapies. This Phase 1a/b study is being conducted with support from an investment from the Cancer Focus Fund, LP and the Cancer Prevention and Research Institute of Texas (CPRIT) DP200094.
Disclosures
MD Anderson's relationship with ImmunoGenesis, and all research conducted at MD Anderson related to ImmunoGenesis, has been identified as an institutional financial conflict of interest by MD Anderson's Institutional Conflict of Interest Committee and is managed under an Institutional Conflict of Interest Management and Monitoring Plan. Dr. Curran and Dr. Hong receive compensation as members of the Immunogenesis SAB, and these financial relationships have been disclosed to MD Anderson's Conflict of Interest Committee in accordance with institutional policy.
Contact
ImmunoGenesis
Investors:
James Barlow President and CEO
James.Barlow@immunogenesis.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
12 minutes ago
- Globe and Mail
ServiceNow to Announce Second Quarter 2025 Financial Results on July 23
ServiceNow (NYSE: NOW) today announced that it will release financial results for the second quarter ended June 30, 2025, following the close of market on Wednesday, July 23, 2025. ServiceNow will host a conference call and live webcast to discuss the financial results. Conference Call Details The conference call will begin at 2 p.m. Pacific Daylight Time (21:00 GMT) on July 23, 2025. Interested parties may listen to the call by dialing (888) 330‑2455 (Passcode: 8135305), or if outside North America, by dialing (240) 789‑2717 (Passcode: 8135305). Individuals may access the live teleconference from this webcast ( An audio replay of the conference call and webcast will be available two hours after its completion and will be accessible for 30 days. To hear the replay, interested parties may go to the investor relations section of the ServiceNow website or dial (800) 770‑2030 (Passcode: 8135305), or if outside North America, by dialing (647) 362‑9199 (Passcode: 8135305). About ServiceNow ServiceNow (NYSE: NOW) is putting AI to work for people. We move with the pace of innovation to help customers transform organizations across every industry while upholding a trustworthy, human centered approach to deploying our products and services at scale. Our AI platform for business transformation connects people, processes, data, and devices to increase productivity and maximize business outcomes. For more information, visit:
Globe and Mail
12 minutes ago
- Globe and Mail
D-Wave Quantum (NYSE: QBTS) Raises $400 Million Through Equity Offering
D-Wave Quantum (NYSE: QBTS) ('D-Wave'), a leader in quantum computing systems, software, and services and the world's first commercial supplier of quantum computers, has completed sales of $400 million in gross proceeds of its common stock under its previously disclosed 'at-the-market' ('ATM') equity offering program. The program, which ran from June 11 to June 27, closed at an average share price of $15.18. This represents a 149% premium over the $6.10 average share price for the sales under the company's prior $150 million ATM program completed in January. The Company intends to use the proceeds from this financing primarily for strategic acquisitions and general corporate purposes including additional working capital and capital expenditures. 'With what we believe to be the strongest balance sheet of any public, independent quantum computing company, we intend to invest in acquisitions and programs that will enable us to expand our already significant lead as the only commercial quantum computing company with applications in production,' said Dr. Alan Baratz, CEO of D-Wave. To view the full press release, visit About D-Wave Quantum Inc. D-Wave is a leader in the development and delivery of quantum computing systems, software, and services. We are the world's first commercial supplier of quantum computers, and the only company building both annealing and gate-model quantum computers. Our mission is to help customers realize the value of quantum, today. Our quantum computers, the world's largest, are available on-premises or via the cloud, supported by 99.9% availability and uptime. More than 100 organizations trust D-Wave with their toughest computational challenges. With over 200 million problems submitted to our quantum systems to date, our customers apply our technology to address use cases spanning optimization, artificial intelligence, research and more. Learn more about realizing the value of quantum computing today and how we're shaping the quantum-driven industrial and societal advancements of tomorrow: Forward Looking Statements Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading 'Risk Factors' discussed under the caption 'Item 1A. Risk Factors' in Part I of our most recent Annual Report on Form 10-K or any updates discussed under the caption 'Item 1A. Risk Factors' in Part II of our Quarterly Reports on Form 10-Q and in our other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law. Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: Corporate Communications
Globe and Mail
29 minutes ago
- Globe and Mail
AMAT's High Margin Solutions Gain Traction: How Long Will it Sustain?
Applied Materials ' AMAT gross margin has been experiencing positive momentum for the past four quarters and came in at 49.2% in the second quarter of fiscal 2025, which is also the highest gross margin since the fourth quarter of fiscal 2000. A favorable mix of products and traction in high-margin solutions led to its robust performance. As the demand for semiconductors used in AI and high performance computing (HPC) is rising, AMAT's leading-edge logic foundry solutions are also on the rise. Strong demand for AMAT's Sym3 Magnum etch system, Cold Field Emission eBeam technology, gate-all-around, backside power delivery, and 3D DRAM technology nodes supports margin expansion. AMAT's Sym3 Magnum etch system is gaining traction because of its capability to develop high-aspect-ratio structures in 3D NAND, DRAM and logic, which are powering AI and HPC workloads. Its Sym3 Magnum etch system has generated more than $1.2 billion in revenues since its launch in February 2024. The Cold Field Emission eBeam technology, which is used in detecting defects at the nanometer scale, is also crucial for high-performance chip manufacturing and testing. Significant growth in AMAT's memory segment, including its advanced DRAM technologies, is also an upside. In the second quarter of fiscal 2025, management projected that revenues from its advanced DRAM customers to grow more than 40% in fiscal 2025. AMAT expects gross margins to remain strong as demand for high-performance computing and AI continues to grow. For the third quarter of fiscal 2025, AMAT has guided a gross margin of 48.3%. How Competitors Fare Against AMAT AMAT faces intense competition from Lam Research LRCX and ASML Holding ASML across 3D DRAM architectures, EUV Lithography, deposition and etching. Both Lam Research and ASML Holding have seen growth in gross margin. However, ASML expects the second half of the year to fetch comparatively lower gross margin due to the revenue recognition from low-margin High Numerical Aperture EUV tools and lower upgrade revenues. Lam Research continues to project a strong gross margin for the upcoming quarter. It expects to deliver a gross margin of 49.5%, which would be a new record if delivered. AMAT's Price Performance, Valuation and Estimates Shares of Applied Materials have gained 13.3% year to date compared with the Electronics - Semiconductors industry's growth of 11.5%. AMAT YTD Price Performance Chart From a valuation standpoint, Applied Materials trades at a forward price-to-sales ratio of 4.94X, lower than the industry's average of 8.5X. AMAT Forward 12 Months (P/S) Valuation Chart Image Source: Zacks Investment Research The Zacks Consensus Estimate for Applied Materials' fiscal 2025 and 2026 earnings implies year-over-year growth of 9.5% and 5.6%, respectively. The estimates for fiscal 2025 and 2026 have been revised upward in the past 30 days. Image Source: Zacks Investment Research Applied Materials currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Zacks' Research Chief Names "Stock Most Likely to Double" Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest. This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report ASML Holding N.V. (ASML): Free Stock Analysis Report Applied Materials, Inc. (AMAT): Free Stock Analysis Report
